Actively Recruiting
Evaluating Pola-ZR-Glo Treatment for Older Patients 70 with Large B-Cell Lymphoma Who Have Not Had Prior Therapy
Led by Ruijin Hospital · Updated on 2026-05-08
30
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of the Pola-ZR-Glo regimen, which combines Polatuzumab Vedotin, Zanubrutinib, Lenalidomide, and Glofitamab, in older patients who have not previously received treatment for large B-cell lymphoma LBCL. This phase 2, single-center, open-label study focuses on patients aged 70 and above who are either unfit or frail, or who decline immunochemotherapy, to understand how well this treatment works and its safety profile in this group. The Pola-ZR-Glo treatment is given in cycles lasting 21 days each, with a total of 12 cycles planned. Polatuzumab vedotin is administered intravenously on specific days during the first six cycles, Zanubrutinib is taken orally twice daily during the first six cycles, and Lenalidomide is taken orally daily from day 2 to day 11 of each of these cycles. Glofitamab is given intravenously following a step-up dosing schedule starting in the first cycle and continuing through the twelfth cycle. Additionally, a single dose of obinutuzumab is given intravenously at the start of the first cycle. Participants will be closely monitored through the study, which includes assessments of disease progression, response to treatment, survival, and treatment-related side effects for up to approximately two years, with some safety follow-up extending up to four years. Researchers will use various measures such as progression-free survival, event-free survival, and response rates at multiple points during treatment cycles. Patient-reported outcomes and adverse events will also be recorded to assess the overall impact and safety of the regimen.
CONDITIONS
Brief Title
The Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL
Research Team
W
Weili Zhao
P
Pengpeng Xu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here